AbbVie (ABBV) wins FDA approval for venetoclax+acalabrutinib, first all‑oral fixed‑duration frontline CLL
- AbbVie announces FDA approval of oral venetoclax plus acalabrutinib as first‑line, fixed‑duration treatment for untreated CLL.
- AbbVie says the regimen offers a time‑limited targeted strategy aiming to provide patients treatment‑free intervals versus continuous therapy.
- Svetlana Kobina, AbbVie VP, highlights oral, fixed‑duration approach may reduce prolonged treatment burden and management complexity.
AbbVie wins FDA clearance for first all‑oral, fixed‑duration frontline CLL regimen
AbbVie announces that the U.S. Food and Drug Administration approves a supplemental new drug application for the all‑oral combination of VENCLEXTA (venetoclax) and acalabrutinib as a first‑line treatment for previously untreated adults with chronic lymphocytic leukemia (CLL). The approval, supported by data from the AstraZeneca‑sponsored Phase 3 AMPLIFY trial, designates the regimen as the first and only all‑oral, fixed‑duration option in that setting and positions AbbVie to offer a time‑limited targeted strategy intended to give patients treatment-free intervals compared with continuous therapies.
The AMPLIFY trial is a global, multicenter study that compares the venetoclax‑acalabrutinib combination, given for a fixed duration of 14 cycles of 28 days, against investigator‑choice chemoimmunotherapy (fludarabine‑cyclophosphamide‑rituximab or bendamustine‑rituximab) given for six cycles. The approval applies to previously untreated patients without del(17p) or TP53 mutation, reflecting the trial’s enrollment criteria and underpinning the regulatory filing. AbbVie frames the label extension as expanding front‑line choices for clinicians managing a disease that often requires long durations of care.
Company executives and patient advocates signal the approval as a meaningful clinical option. Svetlana Kobina, AbbVie’s vice president of global medical affairs, oncology, emphasizes that oral administration and a fixed‑duration approach may reduce the burden of prolonged treatment and complex ongoing management. Dr. Brian Koffman of the CLL Society highlights the value to patients of an oral, time‑limited front‑line option available in the United States.
Trial backbone and partner role
AMPLIFY is sponsored by AstraZeneca and serves as the primary evidence base for the sNDA; it evaluates the combination either alone or with obinutuzumab against standard chemoimmunotherapy in previously untreated patients without high‑risk TP53 mutations. The trial’s fixed‑duration schema—14 28‑day cycles for the venetoclax‑acalabrutinib arm—reflects a deliberate strategy to test time‑limited targeted therapy versus continuous or shorter chemo regimens.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

